Search clinical trials for: Solifenacin succinate placebo

Total 54191 results

Center Eugene Marquis

Terminated

Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer (VesiCaP)

Overactive Bladder

France
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Inc

Completed

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate | Bioavailability of Solifenacin Succinate

United States
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Stamford Hospital

Withdrawn

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

Overactive Bladder | Urge Incontinence | Urinary Urge

United States
University of South Florida

Withdrawn

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

Urinary Incontinence | Parkinson's Disease

United States
Dong-A ST Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
Astellas Pharma Inc

Completed

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate

United States
Astellas Pharma Inc

Completed

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (SUNRISE)

Urinary Bladder, Overactive

France, United Kingdom, Belgium, Germany, Spain, Portugal, Greece, Russian Federation, Czech Republic, Poland, Hungary, Italy, Slovakia, Egypt
University of South Florida

Completed

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease (URGE-PD)

Overactive Bladder in Parkinson's Disease

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Urinary Incontinence

United States, Canada
Advanced Research Network
Astellas Pharma US, Inc.

Terminated

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Over-Active Bladder

United States
Astellas Pharma Inc

Completed

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) (VENUS)

Urinary Bladder, Overactive

United States
Dong-A ST Co., Ltd.

Completed

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers

Overactive Bladder
Shanghai University of Traditional Chinese Medicine
Longhua Hospital

Recruiting

Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder

Overactive Bladder

China
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Beni-Suef University

Completed

Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms

Voiding Disorders

Egypt
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

United States, Belgium, Brazil, Denmark, Hungary, Korea, Republic of, Mexico, Philippines, Poland, Turkey
Astellas Pharma Inc

Completed

Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms (VOLT)

Urinary Bladder, Overactive

United States
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
Astellas Pharma Inc

Completed

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (SHRINK)

Overactive Bladder | Detrusor Overactivity

Belgium, Norway, Spain, Sweden, Italy, Czech Republic, Hungary, France, Canada, Germany, Austria, United Kingdom, Bulgaria, Russian Federation, United States, Poland, Slovakia, Turkey, Israel, Romania
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
Astellas Pharma Inc

Completed

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder (VERSUS)

Urinary Bladder, Overactive

United States
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Cleveland Clinic Florida
Astellas Pharma US, Inc.

Terminated

Over Active Bladder Patients Having Sling Surgery

Overactive Bladder

United States
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Astellas Pharma Inc

Completed

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Czech Republic, Poland, Hungary, Belgium, Germany
Pfizer

Terminated

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Healthy

United States
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Astellas Pharma Inc

Completed

Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR)

Urinary Bladder, Overactive

France, United Kingdom, Spain, Belarus, Belgium, Ukraine, Denmark, Greece, Russian Federation, Czech Republic, Netherlands, Germany, Hungary, Italy, Slovakia, Sweden, Norway
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Rambam Health Care Campus

Unknown

Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms

Urinary Bladder, Overactive

Israel
Peking Union Medical College Hospital
Astellas Pharma China, Inc.; Beijing CAT Science Co., Ltd.

Completed

Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women (OAB)

Overactive Bladder | Urination Disorders | Postmenopausal Disorder

China
Dr Cipto Mangunkusumo General Hospital
Astellas Pharma Indonesia Inc.; Pharos Life Corporation

Unknown

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

Urinary Tract Infection

Indonesia
Astellas Pharma Inc

Completed

A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

Urinary Bladder, Overactive

China
Bay State Clinical Trials, Inc.

Terminated

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

Overactive Bladder

United States
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8577 in Patients With Overactive Bladder

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH (SATURN)

Lower Urinary Tract Symptoms | Prostatic Hyperplasia

France, Poland, Germany, Spain, Finland, Netherlands, Russian Federation, Czech Republic, Hungary, Norway, Denmark, Slovakia, Sweden, Austria, Portugal, United Kingdom
KYU-SUNG LEE
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks

Overactive Bladder

Korea, Republic of
Loyola University
Astellas Pharma US, Inc.

Completed

Bacterial Genomic Sequencing in Overactive Bladder

Overactive Bladder

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment (RESORT-2)

Over Active Bladder

Korea, Republic of
Seattle Urology Research Center

Unknown

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

Nocturia | Urinary Urgency | Urinary Frequency

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. (VICTOR)

Urinary Incontinence

United States
Timothy Boone, MD, PhD
Astellas Pharma US, Inc.

Completed

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms (LUTS)

Lower Urinary Tract Symptoms

United States
Loyola University
Astellas Pharma US, Inc.

Completed

Incontinence & Intimate Partners: Assessing the Contribution of Treatment (IIMPACT)

Urge Urinary Incontinence

United States
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more

Search clinical trials for: Solifenacin succinate placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations